Adam Stein

Associate

adam-stein
  • JD, New York University School of Law, 2018; Staff Editor, Journal of Intellectual Property & Entertainment Law
  • BA (Government), Cornell University, 2013

Qualifications

  • Not admitted in the District of Columbia. Supervised by Ropes & Gray LLP partners who are members of the District of Columbia Bar.
  • Massachusetts, 2018
  • New York, 2021

Adam Stein

Associate

Adam Stein joined Ropes & Gray’s corporate department in 2018. Adam represents clients in a variety of corporate and commercial transactions, including minority equity investments, intellectual property licensing and collaboration transactions and mergers and acquisitions, as well as start-up, formation and corporate governance matters.

Experience

  • Represented The TJX Companies, Inc. in its $225 million minority investment in Familia Trading S.à. r.l., a leading off-price retailer in Russia.
  • Represented Tmunity Therapeutics, Inc., a private clinical stage biotherapeutics company, in connection with its $75 million Series B financing, as well as on various ongoing corporate and commercial matters.
  • Represented Cyteir Therapeutics, Inc., a private clinical stage biotherapeutics company, in connection with its $40 million Series B financing extension and $80 million Series C financing, as well as on various ongoing corporate and commercial matters.
  • Represents various venture capital, institutional and strategic investors in venture and growth equity investments in companies in the technology, health care and biotechnology sectors.
  • Represented a global pharmaceutical company in a collaboration and license agreement with a publicly traded biotechnology company to develop and commercialize anti-viral conjugates for the prevention and treatment of seasonal and pandemic influenza. The pharmaceutical company may pay up to $780 million in upfront, milestone and R&D payments, plus potential future royalties.
  • Represented a global pharmaceutical company in a collaboration and license agreement to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders. The pharmaceutical company may pay up to $1.3 billion in upfront and milestone payments, plus potential future royalties.
  • Represented a global pharmaceutical company in its acquisition of a preclinical biotechnology company for $245 million plus contingent consideration.
  • Represented a global pharmaceutical company in its acquisition of a gene therapy asset for the treatment of age-related macular degeneration.
  • JD, New York University School of Law, 2018; Staff Editor, Journal of Intellectual Property & Entertainment Law
  • BA (Government), Cornell University, 2013

Qualifications

  • Not admitted in the District of Columbia. Supervised by Ropes & Gray LLP partners who are members of the District of Columbia Bar.
  • Massachusetts, 2018
  • New York, 2021
Cookie Settings